Company news
Beam Therapeutics Inc. (NASDAQ:BEAM) news
Every Beam Therapeutics Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer
September 1, 2026
Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences
August 31, 2026
Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Tr...
August 4, 2026
Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral...
July 23, 2026
Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by ...
June 18, 2026
Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American ...
May 18, 2026
Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1
May 13, 2026
Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference
May 13, 2026
Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red B...
May 12, 2026
Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
May 7, 2026
Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New Engl...
April 1, 2026
Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficien...
March 25, 2026
Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in ...
February 24, 2026
Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street
February 24, 2026
Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease ...
February 23, 2026
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical P...
January 11, 2026
Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
December 18, 2025
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differe...
December 6, 2025
Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference
November 12, 2025
Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
November 4, 2025
Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematolog...
November 3, 2025
Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences
August 25, 2025
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of S...
August 14, 2025
Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitryps...
August 5, 2025
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Di...
June 13, 2025
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
June 3, 2025
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
May 29, 2025
Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress
May 14, 2025
Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference
May 13, 2025
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of A...
May 12, 2025
Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
May 6, 2025
Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Re...
April 5, 2025
Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Defic...
March 27, 2025
Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstra...
March 10, 2025
Beam Therapeutics Announces Pricing of Underwritten Offering
March 10, 2025
Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts
February 25, 2025
Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences
February 24, 2025
Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference
January 30, 2025
Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT...
January 23, 2025
Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts
January 13, 2025
Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 17, 2024
Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Co...
December 8, 2024
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hemat...
December 7, 2024
Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer
December 6, 2024
Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader
December 4, 2024
Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference
November 12, 2024
Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs
November 5, 2024
Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCA...
November 5, 2024
Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH ...
October 29, 2024
Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results
August 6, 2024